Alnylam Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$1.31 | -$0.93 | -$1.12 |
| Q2 2024 | 5 | -$1.25 | -$0.89 | -$1.07 |
| Q3 2024 | 6 | -$1.08 | -$0.76 | -$0.92 |
| Q4 2024 | 15 | -$0.90 | -$0.05 | -$0.59 |
| Q1 2025 | 7 | -$1.03 | -$0.18 | -$0.71 |
| Q2 2025 | 3 | -$0.86 | -$0.61 | -$0.73 |
| Q3 2025 | 6 | -$0.54 | -$0.38 | -$0.46 |
| Q4 2025 | 5 | $0.04 | $0.06 | $0.05 |
| Q1 2026 | 4 | $0.37 | $0.52 | $0.45 |
| Q2 2026 | 3 | $0.50 | $0.71 | $0.60 |
| Q3 2026 | 2 | $1.01 | $1.42 | $1.21 |
| Q4 2026 | 2 | $1.23 | $1.73 | $1.47 |
Alnylam Pharmaceuticals, Inc. Earnings Date And Information
Alnylam Pharmaceuticals, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $-0.5 earnings per share for the quarter, topping analysts' consensus estimates of $-0.91663 by $0.41663. The company had revenue of 420.15 M for the quarter and had revenue of 1.83 B for the year. Alnylam Pharmaceuticals, Inc. has generated $-4 earnings per share over the last year ($-3.52 diluted earnings per share) and currently has a price-to-earnings ratio of -104.47. Alnylam Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based on prior year's report dates.
Alnylam Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | -$0.92 | -$0.87 | 0.05 | $532.91 M | $420.15 M |
| 08/01/2024 | Q2 2024 | -$1.07 | -$0.13 | 0.94 | $447.22 M | $659.83 M |
| 05/02/2024 | Q1 2024 | -$1.12 | -$0.52 | 0.6 | $494.33 M | |
| 02/15/2024 | Q4 2023 | -$1.20 | -$1.10 | 0.1 | $439.72 M | |
| 11/02/2023 | Q3 2023 | -$1.34 | $1.18 | 2.52 | $396.76 M | $750.53 M |
| 08/03/2023 | Q2 2023 | -$1.72 | -$2.21 | -0.49 | $332.28 M | $318.75 M |
| 05/04/2023 | Q1 2023 | -$1.97 | -$1.40 | 0.57 | $319.29 M | |
| 02/23/2023 | Q4 2022 | -$2.13 | -$1.68 | 0.45 | $335.04 M | |
| 10/27/2022 | Q3 2022 | -$1.86 | -$3.32 | -1.46 | $291.66 M | $264.31 M |
| 07/28/2022 | Q2 2022 | -$1.62 | -$2.29 | -0.67 | $255.56 M | $224.82 M |
| 04/28/2022 | Q1 2022 | -$1.93 | -$2.00 | -0.07 | $213.26 M | |
| 02/10/2022 | Q4 2021 | -$1.47 | -$2.16 | -0.69 | $258.54 M | |
| 10/28/2021 | Q3 2021 | -$1.51 | -$1.72 | -0.21 | $218.72 M | $187.63 M |
| 08/03/2021 | Q2 2021 | -$1.57 | -$1.61 | -0.04 | $192.05 M | $220.55 M |
| 04/29/2021 | Q1 2021 | -$1.75 | -$1.71 | 0.04 | $177.57 M | |
| 02/11/2021 | Q4 2020 | -$1.93 | -$2.09 | -0.16 | $163.56 M | |
| 11/05/2020 | Q3 2020 | -$1.75 | -$2.18 | -0.43 | $119.05 M | $125.85 M |
| 08/06/2020 | Q2 2020 | -$1.79 | -$1.56 | 0.23 | $98.76 M | $103.96 M |
| 05/06/2020 | Q1 2020 | -$1.89 | -$1.62 | 0.27 | $99.48 M | |
| 02/13/2020 | Q4 2019 | -$2.47 | $71.68 M |
Alnylam Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Alnylam Pharmaceuticals, Inc.'s earnings date?
Alnylam Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based off last year's report dates.
-
Did Alnylam Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Alnylam Pharmaceuticals, Inc. (:ALNY) reported $-0.5 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.91663 by $0.41663.
-
How can I listen to Alnylam Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Alnylam Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Alnylam Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Alnylam Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Alnylam Pharmaceuticals, Inc. generate each year?
Alnylam Pharmaceuticals, Inc. (:ALNY) has a recorded annual revenue of $1.83 B.
-
How much profit does Alnylam Pharmaceuticals, Inc. generate each year?
Alnylam Pharmaceuticals, Inc. (:ALNY) has a recorded net income of $1.83 B. Alnylam Pharmaceuticals, Inc. has generated $-3.52 earnings per share over the last four quarters.
-
What is Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio?
Alnylam Pharmaceuticals, Inc. (:ALNY) has a price-to-earnings ratio of -104.47 and price/earnings-to-growth ratio is 0.29.
